The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer

被引:0
|
作者
Gok, Gamze [1 ]
Kucuk, Tarik [2 ,3 ]
Cimen, Sertac [2 ,3 ]
Gok, Alper [2 ,3 ]
Goktug, Goksel [2 ,3 ]
Erel, Ozcan [1 ]
Imamoglu, Muhammet Abdurrahim [2 ,3 ]
机构
[1] Ankara Bilkent City Hosp, Dept Biochem, TR-06800 Ankara, Turkiye
[2] Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Fac Med, Dept Urol, TR-06110 Ankara, Turkiye
[3] Etlik City Hosp, Dept Urol, TR-06010 Ankara, Turkiye
关键词
bladder cancer; oxidative stress; glutathione; oxidants/antioxidants; RISK;
D O I
10.3390/jcm13185483
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Glutathione, along with its related enzymes, constitutes a key antioxidant defense mechanism against oxidative stress and cancer formation in the body. Among urological malignancies, bladder cancer ranks second following prostate cancer. Oxidative stress has significant involvement in the development and prognosis of bladder cancer. This investigation aimed to examine the impact of glutathione on prognosis in patients with non-muscle-invasive bladder cancer. Methods: This study included 98 patients with high grade non-muscle-invasive bladder cancer who had undergone intravesical Bacillus Calmette-Gu & eacute;rin therapy and 30 healthy controls with no history of uroepithelial carcinoma of the bladder. The patients with bladder cancer were evaluated in three subgroups. Group 1 consisted of 41 patients who did not experience recurrence during follow-up, Group 2 included 28 patients who had recurrent tumors, and Group 3 consisted of 29 patients who progressed to muscle-invasive stages. Blood samples were collected from all participants. Blood levels of reduced, oxidized, and total glutathione were measured spectrophotometrically. Results: Reduced glutathione levels significantly differed among the groups (p < 0.001), attributed to the control group exhibiting higher reduced glutathione levels compared with Groups 1, 2, and 3 (p < 0.001). There were no significant differences in reduced glutathione levels between Groups 1 and 2, Groups 1 and 3, or Groups 2 and 3 (p > 0.05). Total glutathione levels varied significantly among the groups (p < 0.001), with the control group having higher levels than Groups 1, 2, and 3 (p < 0.001). No significant differences were detected between any of the paired patient groups in terms of total glutathione levels (p > 0.05). Regarding oxidized glutathione levels, the difference was statistically significant (p < 0.001), with the control group showing lower levels than the remaining three groups (p < 0.001). Paired comparisons revealed no significant differences in oxidized glutathione levels (p > 0.05). Conclusions: This study revealed that glutathione had an effect on the emergence of bladder cancer but did not affect its prognosis. Nevertheless, we recommend that future studies with larger bladder cancer patient cohorts should be conducted to comprehensively determine the impact of glutathione on the prognosis of this cancer.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Non-muscle-invasive bladder cancer: The role of radical cystectomy
    Chang, SS
    Cookson, MS
    UROLOGY, 2005, 66 (05) : 917 - 922
  • [42] Extravasation of Intravesical Chemotherapy for Non-Muscle-Invasive Bladder Cancer
    Mertens, Laura S.
    Meinhardt, Wim
    Rier, Walther B.
    Nooter, Ronald I.
    Horenblas, Simon
    UROLOGIA INTERNATIONALIS, 2012, 89 (03) : 332 - 336
  • [43] Intravesical Instillation Treatment of Non-muscle-invasive Bladder Cancer
    Braasch, Matthew R.
    Boehle, Andreas
    O'Donnell, Michael A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (07) : 549 - 555
  • [44] Clinical trial design for non-muscle-invasive bladder cancer
    Wei Shen Tan
    Emma Hall
    Ashish M. Kamat
    John D. Kelly
    Nature Reviews Urology, 2023, 20 : 575 - 576
  • [45] Quality of life in patients with non-muscle-invasive bladder cancer
    Alejandro Sanchez
    Matthew F. Wszolek
    Nature Reviews Urology, 2015, 12 : 186 - 188
  • [46] Update on intravesical agents for non-muscle-invasive bladder cancer
    Shariat, Shahrokh F.
    Chade, Deher C.
    Karakiewicz, Pierre I.
    Scherr, Douglas S.
    Dalbagni, Guido
    IMMUNOTHERAPY, 2010, 2 (03) : 381 - 392
  • [47] Radical cystectomy in the treatment of non-muscle-invasive bladder cancer
    Safiullin, K. N.
    Karyakin, O. B.
    ONKOUROLOGIYA, 2012, 8 (02): : 40 - 43
  • [48] Role of Repeat Resection in Non-Muscle-Invasive Bladder Cancer
    Herr, Harry W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (08): : 1041 - 1046
  • [49] Prognostic factors of survival in non-muscle-invasive bladder cancer
    Alekseev, B. Ya.
    Andreeva, Yu. Yu.
    Novikova, I. V.
    ONKOUROLOGIYA, 2013, 9 (01): : 34 - 42
  • [50] Unsupervised nuclei classification in non-muscle-invasive bladder cancer
    Koeller, M.
    Zikken, L.
    Klaeger, J.
    Wasinger, G.
    Kaltenecker, C.
    Oszwald, A.
    Comperat, E.
    VIRCHOWS ARCHIV, 2024, 485 : S171 - S171